Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism.
D000339:Affect / Q000187:drug effects; D000547:Amantadine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000188:drug therapy; D002986:Clinical Trials as Topic; D005069:Evaluation Studies as Topic; D005260:Female; D005476:Fluphenazine / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009966:Orphenadrine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D010919:Placebos; D012559:Schizophrenia / Q000188:drug therapy
D010919:Placebos; D009966:Orphenadrine; D000547:Amantadine; D005476:Fluphenazine